Immunogenicity Testing and Antibody Humanization
Antitope is pioneering a new generation of immunogenicity testing, antibody humanization and protein engineering technologies.
Our mission is to apply these technologies to create improved non-immunogenic biologics. Formed in 2004, Antitope provides proprietary technologies as a comprehensive service for the preclinical prediction of clinical immunogenicity, and for the generation of humanized antibodies, therapeutic proteins and recombinant vaccines. To date, we have entered into multiple agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biologics.
News & Press
Antitope Ltd., Announces Protein Deimmunisation Research Agreement with Research Corporation Technologies, Inc.
Cambridge, UK, 22nd April 2012 - Antitope Ltd, UK ("Antitope") today announced a Research Agreement with Research Corporation Technologies Inc., USA...
Antitope Ltd. and Eden Biodesign Ltd. enter into a Research Agreement
Cambridge UK, February 2013 - Antitope Ltd. (UK) today announced a Research Agreement with Eden Biodesign Ltd. (Liverpool, UK) for the development of therapeutic...